CA1040532A - Process for producing solid bismuth-containing pharmaceutical compositions - Google Patents
Process for producing solid bismuth-containing pharmaceutical compositionsInfo
- Publication number
- CA1040532A CA1040532A CA218,092A CA218092A CA1040532A CA 1040532 A CA1040532 A CA 1040532A CA 218092 A CA218092 A CA 218092A CA 1040532 A CA1040532 A CA 1040532A
- Authority
- CA
- Canada
- Prior art keywords
- dry powder
- bismuth
- pharmaceutical composition
- bi2o3
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/29—Antimony or bismuth compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/02—Ammonia; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
ABSTRACT OF THE DISCLOSURE
A process for producing an effective anti-ulcer preparation in the form of a dry powder by spray-drying a colloidal solution comprising bismuth citrate, ammonia and a polyhydric alcohol.
A process for producing an effective anti-ulcer preparation in the form of a dry powder by spray-drying a colloidal solution comprising bismuth citrate, ammonia and a polyhydric alcohol.
Description
The invention relates to new pharmaceutical compositions and to a process for their preparation.
The new pharmaceutical compositions according to the invention are bismuth-containing anti-ulcer preparations in solid form.
Liquid compositions prepared from bismuth salts, such as bismuth citrate or bismuth subnitrate are known. Such liquid preparations have the disadvantage that they are less easy to store and to transport than solid compositions. They cannot easily be converted into an effective solid product, e.g. by -, simply heating and drying.
According to the invention an aqueous, colloidal solution comprising effective quantities of bismuth citrate~
, ammonia and a polyhydric alcohol is converted into a new i pharmaceutical composition in the form of a dry powder by spray-drying. The liquid starting material optionally contains pepsin, a colouring agent such as carminel an alkali metal (e.g. sodium , or potassium) hydroxide and a preservative, such as the mixture of soluble salts of esters of p-hydroxybenzoic acid, sold under the trade name Nipacombin A. The known liquid preparations j sometimes contain volatile liquids, such as ethanol and chloroform.
Such liquids may be present in the starting material for the -process of the invention in an amount not exceeding 15%, but they ~ have virtually no effect on the process or on the product 'i' obtained. Generally speaking, the commerically available liquid -preparations comprising bismuth citrate, ammonia and a polyhydric - alcohol, may be used to carry out the process of the invention.
It is not certain whether the bismuth citrate, ammonia and polyhydric alcohol are present as such in the liquid or whether they form a new molecule or ion. ` '~
The bismuth citrate may be used as such or it can be formed in situ, e.g. from citric acid and a bismuth salt with a - 1- ~, .;, ` ~04~S32 - `
physiologically acceptable anion. The li~uid is most stable at a pH approximately 9. When the pH is considerably lower or higher a precipitate is formed. Especially when the liquid has to be ; stored for some time before spray-drying, it is therefore ;~
recommended to use so much ammonia and alkali metal hydroxide that this pH is attained. The amount of ammonia should at least be sufficient to keep the bismuth in solution. Preferred polyhydric alcohols are disaccharides such as sucrose or maltose.
The fact that the liquid ammoniacal preparations are only stable within a limited pH-range and that the pH can become too low by loss of ammonia, constitutes another disadvantage of said preparations.
The dry powder according to the invention can be produced from the liquid in a conventional spray-drying unit. The `
liquid starting material suitabl~ contains between 11 and 16% of dissolved solids. The solution is preferably preheated at a temperature of 60 to 65 C. The heating time should be such that no undesired reaction takes place. For instance, when sucrose is ~ ~-used, the heating time should not exceed 20 minutes in order to prevent inversion. The solid product resulting from the process according to the invention is very hygroscopic. It is therefore recommended to remove the moisture from the spray-drying unit by preheating, for instance 30 to 60 minutes with an inlet air temperature of about 200 to 250 C and to carry out the drying with air of a low moisture content. During the drying process the inlet air temperature is preferably between 150 and ;
260 C, a temperature between 170 and 190 C being particularly preferred, and the outlet temperature between 50 and 110 C. It ; -will be understood that the liquid should be fed to the unit with ;~
such a speed that the evaporative capacity is sufficient to form a dry powder.
-` The solid products obtained by the described process
The new pharmaceutical compositions according to the invention are bismuth-containing anti-ulcer preparations in solid form.
Liquid compositions prepared from bismuth salts, such as bismuth citrate or bismuth subnitrate are known. Such liquid preparations have the disadvantage that they are less easy to store and to transport than solid compositions. They cannot easily be converted into an effective solid product, e.g. by -, simply heating and drying.
According to the invention an aqueous, colloidal solution comprising effective quantities of bismuth citrate~
, ammonia and a polyhydric alcohol is converted into a new i pharmaceutical composition in the form of a dry powder by spray-drying. The liquid starting material optionally contains pepsin, a colouring agent such as carminel an alkali metal (e.g. sodium , or potassium) hydroxide and a preservative, such as the mixture of soluble salts of esters of p-hydroxybenzoic acid, sold under the trade name Nipacombin A. The known liquid preparations j sometimes contain volatile liquids, such as ethanol and chloroform.
Such liquids may be present in the starting material for the -process of the invention in an amount not exceeding 15%, but they ~ have virtually no effect on the process or on the product 'i' obtained. Generally speaking, the commerically available liquid -preparations comprising bismuth citrate, ammonia and a polyhydric - alcohol, may be used to carry out the process of the invention.
It is not certain whether the bismuth citrate, ammonia and polyhydric alcohol are present as such in the liquid or whether they form a new molecule or ion. ` '~
The bismuth citrate may be used as such or it can be formed in situ, e.g. from citric acid and a bismuth salt with a - 1- ~, .;, ` ~04~S32 - `
physiologically acceptable anion. The li~uid is most stable at a pH approximately 9. When the pH is considerably lower or higher a precipitate is formed. Especially when the liquid has to be ; stored for some time before spray-drying, it is therefore ;~
recommended to use so much ammonia and alkali metal hydroxide that this pH is attained. The amount of ammonia should at least be sufficient to keep the bismuth in solution. Preferred polyhydric alcohols are disaccharides such as sucrose or maltose.
The fact that the liquid ammoniacal preparations are only stable within a limited pH-range and that the pH can become too low by loss of ammonia, constitutes another disadvantage of said preparations.
The dry powder according to the invention can be produced from the liquid in a conventional spray-drying unit. The `
liquid starting material suitabl~ contains between 11 and 16% of dissolved solids. The solution is preferably preheated at a temperature of 60 to 65 C. The heating time should be such that no undesired reaction takes place. For instance, when sucrose is ~ ~-used, the heating time should not exceed 20 minutes in order to prevent inversion. The solid product resulting from the process according to the invention is very hygroscopic. It is therefore recommended to remove the moisture from the spray-drying unit by preheating, for instance 30 to 60 minutes with an inlet air temperature of about 200 to 250 C and to carry out the drying with air of a low moisture content. During the drying process the inlet air temperature is preferably between 150 and ;
260 C, a temperature between 170 and 190 C being particularly preferred, and the outlet temperature between 50 and 110 C. It ; -will be understood that the liquid should be fed to the unit with ;~
such a speed that the evaporative capacity is sufficient to form a dry powder.
-` The solid products obtained by the described process
- 2 -' ', ' ` ~
are a feature of the invention. The powder can be administered orally as such or it may be dissolved in water to produce a palatable solution.
The invention also includes within its scope pharmaceutical compositions in dosage form for oral administration, such as capsules or tablets, containing the therapeutically active dry bismuth preparation as the active ingredient. The compositions may contain pharmaceutically-acceptable carriers.
The tablets may be formulated in the usual manner with one or more pharmaceutically-acceptable diluents or excipients, for example lactose or starch, and include materials of a lubricating nature, for example calcium stearate or magnesium stearate. Capsules made of absorbable materials, such as yelatin, may contain the active substance alone or in admixture with a .
solid or li~uid diluent.
The compositions according to the invention are ; therapeutically effective in the treatment of peptic ulcer, s including gastric, duodenal and post-operative ulcer and peptic l ulcer associated with hiatus hernia. Suitable daily dosages for ~ 20 adult humans correspond to 450 - 1000 mg of Bi2O3. The dosage . ~ . . .
for children will depend on their weight and age and may be calculated by methods commonly used in medical practice. The daily dose for children under lO years will correspond to 150 -400 mg of Bi2O3. The pharmaceutical compositions in dosage form therefore preferably have a bismuth content equivalent to 50 -250 mg of Bi2O3.
The following Example illustrates the process of the invention.
~i . .
Example I
1.500 liter of liquid is prepared from 180.360 kg of bismuth citrate 118.279 1 of ammonia 25%
4~532 ~:
7.125 kg of pepsin 1:10.000 ' 23.700 kg of anhydrous citric acid 0.990 1 of carmine nacarat ' ,' 8.051 1 of glycerol ~ ' 330.000 kg of sucrose 39.900 kg of potassium hydroxide
are a feature of the invention. The powder can be administered orally as such or it may be dissolved in water to produce a palatable solution.
The invention also includes within its scope pharmaceutical compositions in dosage form for oral administration, such as capsules or tablets, containing the therapeutically active dry bismuth preparation as the active ingredient. The compositions may contain pharmaceutically-acceptable carriers.
The tablets may be formulated in the usual manner with one or more pharmaceutically-acceptable diluents or excipients, for example lactose or starch, and include materials of a lubricating nature, for example calcium stearate or magnesium stearate. Capsules made of absorbable materials, such as yelatin, may contain the active substance alone or in admixture with a .
solid or li~uid diluent.
The compositions according to the invention are ; therapeutically effective in the treatment of peptic ulcer, s including gastric, duodenal and post-operative ulcer and peptic l ulcer associated with hiatus hernia. Suitable daily dosages for ~ 20 adult humans correspond to 450 - 1000 mg of Bi2O3. The dosage . ~ . . .
for children will depend on their weight and age and may be calculated by methods commonly used in medical practice. The daily dose for children under lO years will correspond to 150 -400 mg of Bi2O3. The pharmaceutical compositions in dosage form therefore preferably have a bismuth content equivalent to 50 -250 mg of Bi2O3.
The following Example illustrates the process of the invention.
~i . .
Example I
1.500 liter of liquid is prepared from 180.360 kg of bismuth citrate 118.279 1 of ammonia 25%
4~532 ~:
7.125 kg of pepsin 1:10.000 ' 23.700 kg of anhydrous citric acid 0.990 1 of carmine nacarat ' ,' 8.051 1 of glycerol ~ ' 330.000 kg of sucrose 39.900 kg of potassium hydroxide
3.000 kg of Nipacombin A 0.2%
8.700 1 of chloroform , 94.050 1 of ethanol and purified water to produce the desired volum~.
The solution obtained is diluted with water to a solid~
content of 12% and the diluted liquid is preheated at 60 - 65 C ~` ' for 15 minutes. A spray-drying unit with an evaporatlve capacity of 10 kgs/h is preheated for 30 minutes with an inlet-air ~'' . ~
temperature of 200 C. The liquid is subsequently fed to the ' ~,~ akomizer with a speed of 9 liters per hour, the inlet-air ;' .. . . .... .
temperature being mainta,ined at 180 C, and the dry powder formed is collected. ~ ,,, ' The following Example illustrates a pharmaceutical composition according to the invention.
,, Example II ,' ~'';' Using known pharmaceutical techniques, tablets are prepared, containing 450 mg of the spray-dried product prepared according to Example I, 25 mg of ~erosil 200 (purified silicon dioxide), 50 mg of corn starch ' , , 5 mg of magnesium stearate.
The invention also includes within its scope the , preparation of an aqueous soiution from the dry powder. ~or instance, a solution suitable for oral administration may be ; obtained by dissolving 200 g of the powder prepared according to ~ ' Example I in water to a volume of 1 liter. Other Physiologically-_ 4 _ * Trade Mark ~' .' ~ '' . , '' ~' S3~ ~
acceptable substances may be added, Eor instance to produce a .
desired pH or to improve the taste of the solution. ;:
: ,' . '-.. ~ ,.
'' '';''': '', .
,-, " . ',' ' .
r .. ~ ,.
. . ~ ~ . .
'~ ',~;', '' .
' ' .
,1 1 ' ': ~': ~
' ~
~:3 '~
'' ~
' ,, .
~~ - 5 -., .
:~ . . . . .
8.700 1 of chloroform , 94.050 1 of ethanol and purified water to produce the desired volum~.
The solution obtained is diluted with water to a solid~
content of 12% and the diluted liquid is preheated at 60 - 65 C ~` ' for 15 minutes. A spray-drying unit with an evaporatlve capacity of 10 kgs/h is preheated for 30 minutes with an inlet-air ~'' . ~
temperature of 200 C. The liquid is subsequently fed to the ' ~,~ akomizer with a speed of 9 liters per hour, the inlet-air ;' .. . . .... .
temperature being mainta,ined at 180 C, and the dry powder formed is collected. ~ ,,, ' The following Example illustrates a pharmaceutical composition according to the invention.
,, Example II ,' ~'';' Using known pharmaceutical techniques, tablets are prepared, containing 450 mg of the spray-dried product prepared according to Example I, 25 mg of ~erosil 200 (purified silicon dioxide), 50 mg of corn starch ' , , 5 mg of magnesium stearate.
The invention also includes within its scope the , preparation of an aqueous soiution from the dry powder. ~or instance, a solution suitable for oral administration may be ; obtained by dissolving 200 g of the powder prepared according to ~ ' Example I in water to a volume of 1 liter. Other Physiologically-_ 4 _ * Trade Mark ~' .' ~ '' . , '' ~' S3~ ~
acceptable substances may be added, Eor instance to produce a .
desired pH or to improve the taste of the solution. ;:
: ,' . '-.. ~ ,.
'' '';''': '', .
,-, " . ',' ' .
r .. ~ ,.
. . ~ ~ . .
'~ ',~;', '' .
' ' .
,1 1 ' ': ~': ~
' ~
~:3 '~
'' ~
' ,, .
~~ - 5 -., .
:~ . . . . .
Claims (17)
1. A process for the preparation of a new solid bismuth-containing pharmaceutical composition which comprises converting an aqueous, colloidal solution comprising effective quantities of bismuth citrate, ammonia and a polyhydric alcohol, into a dry powder by spray-drying.
2. The process according to claim 1 in which the solution used as starting material contains between about 11% and about 16%
of dissolved solids.
of dissolved solids.
3. The process according to claim 1 in which the solution used as starting material is preheated at 60° to 65°C.
4. Process according to claim 1 in which the spray-drying unit is preheated and the drying is carried out with air of a low moisture content.
5. Process according to claim 4 in which the spray-drying unit is preheated at 200° to 250°C.
6. Process according to claim 1 in which the spray-drying is carried out in a spray-drying unit wherein the inlet air temperature is between 150° and 260°C.
7. Process according to claim 6 in which the inlet air temperature is between 170° and 190°C.
8. Process according to claim 1 in which the solution used as starting material has a pH of about 9.
9. A new solid bismuth-containing pharmaceutical composition in the form of a dry powder whenever prepared by the process of claim 1, 2 or 3.
10. A new solid bismuth-containing pharmaceutical composition in the form of a dry powder whenever prepared by the process of claim 4, 5 or 6.
11. A new solid bismuth-containing pharmaceutical composition in the form of a dry powder whenever prepared by the process of claim 7 or 8.
12. A pharmaceutical composition in dosage form for oral administration comprising the dry powder obtained from the process of claim 1, 2 or 3, said composition having a bismuth content equivalent to from about 50 mg to about 250 mg of Bi2O3.
13. A pharmaceutical composition in dosage form for oral administration comprising the dry powder obtained from the process of claim 4, 5 or 6, said composition having a bismuth content equivalent to from about 50 mg to about 250 mg of Bi2O3.
14. A pharmaceutical composition in dosage form for oral administration comprising the dry powder obtained from the process of claim 7 or 8, said composition having a bismuth content equivalent to from about 50 mg to about 250 mg of Bi2O3.
15. A tablet composition for oral administration comprising the dry powder obtained from the process of claim 1, 2 or 3, said tablet having a bismuth content equivalent to from about 50 mg to about 250 mg of Bi2O3.
16. A tablet composition for oral administration comprising the dry powder obtained from the process of claim 4, 5 or 6, said tablet having a bismuth content equivalent to from about 50 mg to about 250 mg of Bi2O3.
17. A tablet composition for oral administration comprising the dry powder obtained from the process of claim 7 or 8, said tablet having a bismuth content equivalent to from about 50 mg to about 250 mg of Bi2O3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA00740385A ZA74385B (en) | 1974-01-18 | 1974-01-18 | Pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1040532A true CA1040532A (en) | 1978-10-17 |
Family
ID=25567281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA218,092A Expired CA1040532A (en) | 1974-01-18 | 1975-01-17 | Process for producing solid bismuth-containing pharmaceutical compositions |
Country Status (18)
| Country | Link |
|---|---|
| JP (1) | JPS5837284B2 (en) |
| AT (1) | AT349150B (en) |
| AU (1) | AU485660B2 (en) |
| BE (1) | BE824509A (en) |
| CA (1) | CA1040532A (en) |
| CH (1) | CH622947A5 (en) |
| DE (1) | DE2501787A1 (en) |
| DK (1) | DK151770C (en) |
| ES (1) | ES433908A1 (en) |
| FI (1) | FI750113A (en) |
| FR (1) | FR2258177B1 (en) |
| GB (1) | GB1478742A (en) |
| IE (1) | IE40361B1 (en) |
| IT (1) | IT1036072B (en) |
| LU (1) | LU71668A1 (en) |
| NL (1) | NL185130C (en) |
| SE (1) | SE437930B (en) |
| ZA (1) | ZA74385B (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU179474B (en) * | 1978-02-24 | 1982-10-28 | Laszlo Gyarmati | Process for preparing solid oral pharmaceutical compositons with increased length of activity and with a regulated release of the active material |
| PH20649A (en) * | 1981-09-22 | 1987-03-16 | Gist Brocades Nv | Bismuth containing composition and method for the preparation thereof |
| US4801608A (en) * | 1981-09-22 | 1989-01-31 | Gist-Brocades N. V. | Bismuth containing composition and method for the preparation thereof |
| AU590578B2 (en) * | 1985-04-18 | 1989-11-09 | Procter & Gamble Company, The | Treatment of non-ulcer dyspepsia with bismuth salts |
| US4748113A (en) * | 1985-06-13 | 1988-05-31 | Marshall Barry J | Compositions and methods for the diagnosis of gastrointestinal disorders involving urease |
| EP0206626B2 (en) * | 1985-06-13 | 2002-05-22 | Barry James Dr. Marshall | Use of Bismuth for the manufacture of a medicament for the treatment of gastrointestinal disorders induced by Campylobacter polyridis |
| ATE318144T1 (en) * | 1985-06-13 | 2006-03-15 | Barry James Marshall | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL CONDITIONS, CONTAINING BISMUT AND AN ANTIMICROBIAL AGENT |
| US5256684A (en) * | 1985-06-13 | 1993-10-26 | The Procter & Gamble Company | Methods and compositions for the treatment of gastrointestinal disorders |
| EP0363502B1 (en) * | 1988-10-08 | 1991-09-25 | Dr. R. Pfleger Chemische Fabrik Gmbh | Liquid formulation containing bismuth, process to prepare it and use thereof |
| DE3901508C2 (en) * | 1989-01-19 | 1994-04-07 | Falk Pharma Gmbh | Drug based on a bismuth-containing preparation in solid form |
| IT1229502B (en) * | 1989-01-25 | 1991-09-03 | Euroresearch Srl | COMPOSITIONS CONTAINING BISMUTO SUITABLE FOR THERAPEUTIC USE. |
| IE893167A1 (en) * | 1989-10-04 | 1991-04-24 | Ulso Lab Ltd | Preparation of orally administrable liquids for use in¹therapy |
| ES2084174T3 (en) * | 1990-07-20 | 1996-05-01 | Tillotts Pharma Ag | PRODUCTS AND PROCESSES FOR THE TREATMENT OF THE FOOD DUCT. |
| US5192752A (en) * | 1991-01-14 | 1993-03-09 | The Procter & Gamble Company | Swallowable pharmaceutical compositions containing colloidal bismuth subcitrate |
| US6426085B1 (en) | 1994-05-02 | 2002-07-30 | Josman Laboratories Inc. | Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis |
| US6902738B2 (en) | 1994-05-02 | 2005-06-07 | Josman Laboratories, Inc. | Topical oral dosage forms containing bismuth compounds |
| US5834002A (en) | 1994-05-02 | 1998-11-10 | Josman Laboratories, Inc. | Chewing gum containing colloidal bismuth subcitrate |
| US6379651B1 (en) | 1995-02-07 | 2002-04-30 | Josman Laboratories | Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases |
| US6372784B1 (en) | 1995-02-07 | 2002-04-16 | Josman Laboratories, Inc. | Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds |
| MX9703918A (en) | 1997-05-28 | 1998-11-30 | J Marshall M D Barry | Procedure to prepare a reactive pharmaceutical product to detect gastrointestinal disorder caused by bacteria in superior gastrointestinal tract. |
| US7008777B2 (en) | 2001-10-15 | 2006-03-07 | Barry J. Marshall | System for the detection of urease and method for using same |
| US6998250B2 (en) | 2001-10-15 | 2006-02-14 | Donald J. McMichael | Method for detecting Helicobacter pylori |
| USD484988S1 (en) | 2001-12-17 | 2004-01-06 | Kimberly-Clark Worldwide, Inc. | Diagnostic test kit with specimen-handling tool |
| US6783976B2 (en) | 2001-12-21 | 2004-08-31 | Kimberly-Clark Worldwide, Inc. | Carrier and specimen-handling tool for use in diagnostic testing |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1963781A1 (en) * | 1968-12-23 | 1970-07-09 | Serfontein Willem Jacob | Improved bismuth preparations |
| GB1259151A (en) * | 1968-12-23 | 1972-01-05 | Willem Jacob Serfontein | Bismuth complexes |
-
1974
- 1974-01-18 ZA ZA00740385A patent/ZA74385B/en unknown
-
1975
- 1975-01-14 AU AU77293/75A patent/AU485660B2/en not_active Expired
- 1975-01-16 CH CH51075A patent/CH622947A5/en not_active IP Right Cessation
- 1975-01-16 JP JP50007408A patent/JPS5837284B2/en not_active Expired
- 1975-01-17 DE DE19752501787 patent/DE2501787A1/en active Granted
- 1975-01-17 IE IE86/75A patent/IE40361B1/en unknown
- 1975-01-17 DK DK012675A patent/DK151770C/en not_active IP Right Cessation
- 1975-01-17 LU LU71668A patent/LU71668A1/xx unknown
- 1975-01-17 BE BE152481A patent/BE824509A/en not_active IP Right Cessation
- 1975-01-17 FR FR7501521A patent/FR2258177B1/fr not_active Expired
- 1975-01-17 SE SE7500501A patent/SE437930B/en not_active IP Right Cessation
- 1975-01-17 CA CA218,092A patent/CA1040532A/en not_active Expired
- 1975-01-17 AT AT31875A patent/AT349150B/en not_active IP Right Cessation
- 1975-01-17 ES ES433908A patent/ES433908A1/en not_active Expired
- 1975-01-17 GB GB2146/75A patent/GB1478742A/en not_active Expired
- 1975-01-17 NL NLAANVRAGE7500552,A patent/NL185130C/en not_active IP Right Cessation
- 1975-01-17 IT IT67104/75A patent/IT1036072B/en active
- 1975-01-17 FI FI750113A patent/FI750113A/fi not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| GB1478742A (en) | 1977-07-06 |
| AU7729375A (en) | 1976-07-15 |
| DK151770C (en) | 1989-11-06 |
| SE7500501L (en) | 1975-07-21 |
| DK151770B (en) | 1988-01-04 |
| IT1036072B (en) | 1979-10-30 |
| IE40361B1 (en) | 1979-05-09 |
| FR2258177B1 (en) | 1978-07-21 |
| NL185130C (en) | 1990-02-01 |
| FR2258177A1 (en) | 1975-08-18 |
| LU71668A1 (en) | 1975-06-24 |
| DE2501787A1 (en) | 1975-07-24 |
| DE2501787C2 (en) | 1987-11-12 |
| AU485660B2 (en) | 1977-07-28 |
| SE437930B (en) | 1985-03-25 |
| ZA74385B (en) | 1975-08-27 |
| CH622947A5 (en) | 1981-05-15 |
| JPS5837284B2 (en) | 1983-08-15 |
| NL185130B (en) | 1989-09-01 |
| NL7500552A (en) | 1975-07-22 |
| IE40361L (en) | 1975-07-18 |
| JPS50116623A (en) | 1975-09-12 |
| BE824509A (en) | 1975-07-17 |
| ATA31875A (en) | 1978-08-15 |
| AT349150B (en) | 1979-03-26 |
| DK12675A (en) | 1975-09-15 |
| ES433908A1 (en) | 1976-11-16 |
| FI750113A (en) | 1975-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1040532A (en) | Process for producing solid bismuth-containing pharmaceutical compositions | |
| US4956386A (en) | Pharmaceutical compositions and process for their preparation | |
| US5019563A (en) | Pharmaceutical composition | |
| CA1254143A (en) | Pharmaceutical preparation with a content of ibuprofen, and process for its preparation | |
| US3898328A (en) | Dry stable composition for the treatment of scours and dehydration | |
| EP0011489B1 (en) | An analgesic effervescent powder and process for its preparation | |
| JPS60208979A (en) | Antiinflammatory novel compound obtained by combining beta-chiclodextrin | |
| EP0524579B1 (en) | Improved oral dosing formulations of dideoxy purine nucleosides | |
| US4801608A (en) | Bismuth containing composition and method for the preparation thereof | |
| FI77156C (en) | Process for preparing a solid bismuth-containing composition | |
| Hillyard et al. | Antacid and antiulcer properties of the polysaccharide chitosan in the rat | |
| SU1009467A1 (en) | Agent for dissoluting urine concretions | |
| US3928609A (en) | Non-alcoholic theophylline product | |
| JPH09502709A (en) | Oral, water-soluble pharmaceutical composition containing estrone derivative and calcium salt | |
| US2883327A (en) | Reducing the gelation of methylcellulose by the addition of a neutral, water-soluble, amino carboxylic acid and product thereof | |
| RU2589507C1 (en) | Agent based on dry motherwort extract and method for production thereof | |
| GB2061111A (en) | Long acting pharmaceutical composition | |
| US3655883A (en) | Water soluble magnesium-aluminum antacid composition | |
| JPH0222225A (en) | Solid preparation containing inhibitor of secretion of acid in stomach | |
| JP2000080034A (en) | Composition for cold | |
| JPH03287531A (en) | Remedy for pacreatitis | |
| JPS58116423A (en) | Methanoprostacycline pharmaceutical composition | |
| JPH0322874B2 (en) | ||
| JPS6357520A (en) | Antiulcer agent | |
| Stone | Pharmaceutical application of ferrous gluconate NF |